Serology and nucleic acid amplification are the main diagnostic tools for the diagnosis of Mycoplasma pneumoniae infection. Since no reference standard is generally accepted, serologic assays for M. pneumoniae have not been evaluated on a broad scale. In this study, 12 commercially available serologic assays (for immunoglobulin G [IgG] and IgM) and the complement fixation test (CFT) were evaluated by using M. pneumoniae DNA detection by real-time PCR as the "gold standard." The assays tested were Platelia EIA (Bio-Rad), SeroMP EIA (Savyon), Serion classic EIA (Virion/Serion), Biotest EIA (Biotest), Ridascreen EIA (r-Biopharm), AniLabsystems EIA (Labsystems), Novum EIA (Novum Diagnostica), Diagnosys EIA (MP products), Genzyme/Virotech EIA, ImmunoWell EIA (Genbio), ImmunoCard EIA (Meridian), and SerodiaMycoII microparticle agglutination (Fujirebio). Serum samples (n ؍ 46) from 27 PCR-positive patients with a known first day of disease and sera (n ؍ 33) from PCR-negative controls were obtained from prospective studies of acute lower respiratory tract infections. Additionally, control sera (n ؍ 63) from patients with acute viral or bacterial respiratory infections other than those caused by M. pneumoniae were tested. The results showed low specificities for both the Novum and the ImmunoCard IgM assays. The IgM assays with the best performances in terms of sensitivity and specificity were AniLabsystems (77% and 92%, respectively), SeroMP (71% and 88%, respectively), and CFT (65% and 97%, respectively). Good receiver operating characteristic areas under the curve were found for CFT (0.94), the Platelia assay (0.87), and the AniLabsystems assay (0.85). We conclude that there are few commercial serologic assays for the detection of M. pneumoniae infections with appropriate performances in terms of sensitivity and specificity and that PCR has become increasingly important for the diagnosis of M. pneumoniae infections in defined groups of patients.Mycoplasma pneumoniae is a common cause of upper and lower respiratory tract infections (LRTIs) in humans. The clinical picture is that of a slowly progressing tracheobronchitis with malaise and nonproductive cough (4). In 5 to 10% of patients with M. pneumoniae infection, especially young adults, the infection may cause atypical pneumonia (17). Reinfections with M. pneumoniae do occur, but it is unclear whether persistent carriage of mycoplasmas in an immune subject occurs (5, 8, 13). As M. pneumoniae lacks a cell wall, the commonly described -lactam antibiotics are not effective and adequate laboratory diagnosis is important.Diagnosis of M. pneumoniae infection in routine clinical practice has been based on serology, since bacterial culture of this organism is slow and lacks sensitivity (6, 14). The serologic assays that have been used in the past are immunofluorescence, the complement fixation test (CFT), and the microparticle agglutination (MAG) assay, which are based on antigens derived from crude culture extracts that contain large amounts of cross-reactive glycoli...